Quarterly ResultMay 4, 2026, 04:28 PM
Nuvation Bio Q1 Net Income $5.4M; Acquires Safusidenib Japan Rights
AI Summary
Nuvation Bio Inc. reported a net income of $5.4 million for Q1 2026, a significant improvement from a $53.2 million net loss in the prior year. The company achieved $18.5 million in net product revenues for IBTROZI, with over 200 new patients starting treatment. Nuvation Bio also secured global development and commercialization rights for safusidenib by acquiring the Japan rights from Daiichi Sankyo, and presented updated positive clinical data for IBTROZI at AACR 2026.
Key Highlights
- Net income for Q1 2026 was $5.4 million, compared to a net loss of $53.2 million in Q1 2025.
- Net product revenues for IBTROZI reached $18.5 million in Q1 2026.
- Collaboration and license agreements revenue increased to $64.7 million in Q1 2026 from $3.1 million in Q1 2025.
- Cash, cash equivalents, and marketable securities totaled $533.7 million as of March 31, 2026.
- Acquired Japan rights to safusidenib from Daiichi Sankyo, securing full global development and commercialization rights.
- IBTROZI demonstrated a median duration of response of 49.7 months in TKI-na\u00efve patients with ROS1+ NSCLC.
- Over 600 patients have started IBTROZI since its launch in late June 2025.
- Stephen Dang, Ph.D., was appointed as Chief Legal Officer in March 2026.